Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
Very-high-purity Factor VIII concentrates produced by monoclonal or recombinant technology have been postulated to be more antigenic resulting in an increased risk of inhibitor development in hemophilia A patients. However, previous reports, mainly based on prevalence figures, may have underestimated the "true" risk of this complication in patients treated with less pure Factor VIII concentrates. The present study, started in 1975, has been designed to calculate the risk of inhibitor development in patients with severe or moderate hemophilia A, followed since their first exposure to intermediate or high-purity Factor VIII concentrates, produced by conventional technologies. Sixty-four hemophiliacs fulfilled the enrollment criteria. Inhibitors developed in 20.3% (13/64) of all patients and in 23% (11/48) of those with severe Factor VIII deficiency. Eleven patients manifested a strong anamnestic response after exposure to Factor VIII (high responders) and 2 had low inhibitor concentrations despite repeated Factor VIII infusions (low responders). The incidence of inhibitor development was 24.6 per 1000 patient-years of observation. The cumulative risk of inhibitor formation was 19.9% at age of 6 years, and 20.3% at 5 years after the first exposure. The risk was 19.3% at 70 days of exposure to Factor VIII concentrates, and 17.2% after a total of 50,000 units of Factor VIII given. Further studies are needed to confirm the above risk of acquiring an inhibitor, which indicates an under-estimation by previous studies. In addition, more data is needed to demonstrate whether very-high-purity Factor VIII concentrates may be more antigenic than conventional preparations.
de Biasi
R
R
Divisione di Ematologia, Ospedale Nuovo Pellegrini, Naples, Italy.
Rocino
A
A
Papa
M L
ML
Salerno
E
E
Mastrullo
L
L
De Blasi
D
D
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005069:Evaluation Studies as Topic; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000302:isolation & purification / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000628:therapy*; D006801:Humans; D011446:Prospective Studies; D012307:Risk Factors
D005169:Factor VIII